meloxicam | Arthrosan solution for in / mouse. enter 6 mg / ml 2.5 ml ampoules 3 pcs.
Special Price
$17.46
Regular Price
$26.00
In stock
SKU
BID466640
Release form
Solution for intramuscular administration.
Solution for intramuscular administration.
Release form
Solution for intramuscular administration.
Packing
3 amp. 2.5 ml each.
Pharmacological action
Meloxicam is an NSAID that has anti-inflammatory, antipyretic and analgesic effects. Belongs to the class of oxycams, is a derivative of enolic acid.
The mechanism of action is associated with the inhibition of prostaglandin synthesis as a result of selective inhibition of the enzymatic activity of type 2 cyclooxygenase (COX-2), which is involved in prostaglandin biosynthesis in the area of inflammation. When prescribed in high doses, prolonged use and individual characteristics of the body, selectivity for COX-2 is reduced. To a lesser extent, it affects the first type cyclooxygenase (COX-1), which is involved in the synthesis of prostaglandins that protect the gastrointestinal mucosa and take part in the regulation of blood flow in the kidneys. Due to the indicated selectivity of suppressing the activity of COX-2, the drug less often causes erosive and ulcerative lesions of the gastrointestinal tract.
Indications
Symptomatic treatment of inflammatory and degenerative diseases of the muscular-joint system associated with pain, including:
Osteoarthritis.
Rheumatoid Arthritis.
Ankylosing spondylitis (ankylosing spondylitis).
Osteochondrosis.
Contraindications
Hypersensitivity to meloxicam or auxiliary components of the drug.
Uncompensated heart failure.
Early postoperative period after coronary artery bypass grafting.
Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs.
Exacerbation of peptic ulcer of the stomach and duodenum active gastrointestinal bleeding.
Inflammatory bowel disease (ulcerative colitis, Crohn's disease in the acute stage).
Cerebrovascular bleeding or other bleeding.
Hemophilia and other bleeding disorders.
Severe liver failure or active liver disease.
Chronic renal failure (in patients not undergoing hemodialysis (creatinine clearance less than 30 ml / min)).
Progressive kidney disease, including confirmed hyperkalemia.
Children under 18 years old.
Pregnancy.
Breastfeeding period.
Precautions: in elderly patients and with the following medical history: coronary heart disease, congestive heart failure, cerebrovascular disease, peripheral artery disease, dyslipidemia / hyperlipidemia, diabetes mellitus, chronic renal failure (creatinine clearance 30-60 ml / min) ulcerative lesion of the gastrointestinal tract, the presence of Helicobacter pylori infection, smoking, severe somatic diseases. With prolonged use of NSAIDs, alcohol abuse, concomitant therapy with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., acetylsalicylic acid, clopidogrel), oral glucocorticosteroids (e.g., prednisolone), selective serotonin reuptake inhibitors (e.g., serotonoxinfram, ) the drug should be taken with caution. To reduce the risk of developing adverse effects from the gastrointestinal tract, the minimum effective dose should be used in a short course.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
The drug can change the properties of platelets, but does not replace the preventive effect of acetylsalicylic acid in cardiovascular diseases.
Caution should be exercised when using the drug in patients with a history of gastric and duodenal ulcer and patients on anticoagulant therapy. In such patients, the risk of erosive and ulcerative diseases of the gastrointestinal tract is increased.
Caution should be exercised and daily diuresis and renal function should be monitored when using the drug in the elderly and patients with reduced BCC and reduced glomerular filtration (dehydration, chronic heart failure, cirrhosis of the liver, nephrotic syndrome, clinically pronounced kidney disease, diuretics, dehydration after major surgical operations).
When signs of liver damage appear (skin itching, yellowing of the skin, nausea, vomiting, abdominal pain, dark urine, persistent and significant increase in the level of transaminases and changes in other indicators of liver function), the drug should be stopped and consult your doctor.
After two weeks of using the drug, it is necessary to control the activity of “liver” enzymes.
In patients with a slight or moderate decrease in renal function (CC> 30 ml / min), dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (pruritus, skin rash, urticaria, photosensitivity)
In patients with a slight or moderate decrease in renal function (CC> 30 ml / min), dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (pruritus, skin rash, urticaria, photosensitivity)
In patients with a slight or moderate decrease in renal function (CC> 30 ml / min), dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (pruritus, skin rash, urticaria, photosensitivity)during treatment it is necessary to consult a doctor in order to resolve the issue of discontinuation of the drug.
Meloxicam, like other NSAIDs, can mask the symptoms of infectious diseases.
The use of meloxicam, as well as other drugs that block the synthesis of prostaglandins, can affect fertility, therefore it is not recommended for women planning pregnancy.
Do not use the drug concurrently with other NSAIDs.
Influence on the ability to drive vehicles and control mechanisms
The use of the drug can cause headaches, dizziness and drowsiness. If these phenomena occur, you should refuse to drive vehicles and perform other potentially dangerous activities, requiring increased concentration of attention and speed of psychomotor reactions.
Composition
1 ml of the solution contains:
Active ingredient: meloxicam - 6 mg.
Excipients: glycofurfural (glycofurol) 100 mg, glycine 5 mg, meglumine 3.75 mg, sodium hydroxide solution 1M to pH 8.2-8.9, sodium chloride 3 mg, poloxamer 188 (lutrol F68) 50 mg, water d / and up to 1 ml.
Dosage and administration of
Intramuscular administration of the drug is indicated in the first 2-3 days of treatment. Further treatment is continued with the use of oral forms (tablets). The recommended dose is 7.5 or 15 mg once a day, depending on the intensity of the pain and the severity of the inflammatory process. Since the potential risk of adverse reactions depends on the dose and duration of treatment, the smallest effective doses and the shortest possible short course should be used.
In patients with severe renal failure undergoing hemodialysis, the dose should not exceed 7.5 mg per day.
The drug is administered by deep IM injection. The contents of the ampoules should not be mixed in the same syringe with other drugs. The drug can not be entered in / in.
Side effects of
From the digestive system: more than 1% - dyspepsia, including nausea, vomiting, abdominal pain, diarrhea, constipation, flatulence 0.1-1% - a transient increase in the activity of “liver” transaminases, hyperbilirubinemia, belching, esophagitis, gastric or duodenal ulcer, gastrointestinal bleeding (hidden or overt ), stomatitis less than 0.1% - perforation of the digestive tract, colitis, hepatitis, gastritis.
From the hemopoietic organs: more than 1% - anemia 0.1-1% - leukopenia, thrombocytopenia.
From the skin: more than 1% - itching, skin rash 0.1-1% - urticaria less than 0.1% - photosensitivity, bullous rashes, erythema multiforme, incl. Stevens-Johnson syndrome, toxic epidermal necrolysis.
From the respiratory system: less than 0.1% - bronchospasm.
From the central nervous system: more than 1% - dizziness, headache 0.1-1% - tinnitus, drowsiness less than 0.1% - emotional lability, confusion, disorientation.
From the cardiovascular system: more than 1% - peripheral edema 0.1-1% - increased blood pressure, palpitations, hyperemia of the face.
From the urinary system: 0.1-1% - hypercreatininemia, increased serum urea concentration less than 0.1% - acute renal failure, no connection with meloxicam intake - interstitial nephritis, albuminuria, hematuria.
From the sensory organs: less than 0.1% - conjunctivitis, blurred vision.
Allergic reactions: less than 0.1% - angioedema, anaphylactic, anaphylactoid reactions.
Drug Interactions
When used simultaneously with other NSAIDs (including acetylsalicylic acid), the risk of erosive and ulcerative lesions and gastrointestinal bleeding increases.
With simultaneous use with antihypertensive drugs, the effectiveness of the latter may decrease.
With simultaneous use with lithium preparations, it is possible to develop cumulation of lithium and increase its toxic effect (it is recommended to control the concentration of lithium in the blood).
With simultaneous use with methotrexate, the side effect of the latter on the hematopoietic system is enhanced (the risk of anemia and leukopenia, a periodic general blood test is indicated).
When used simultaneously with diuretics and cyclosporine, the risk of developing renal failure increases.
With simultaneous use with intrauterine contraceptives, the effectiveness of the latter may be reduced.
When used simultaneously with anticoagulants (heparin, warfarin), thrombolytic drugs (streptokinase, fibrinolysin), and antiplatelet agents (ticlopidine, clopidogrel, acetysalicylic acid), the risk of bleeding increases (periodic monitoring of blood coagulability is necessary).
With simultaneous use with colestyramine, the excretion of meloxicam through the gastrointestinal tract is accelerated.
Concomitant use with selective serotonin reuptake inhibitors increases the risk of gastrointestinal bleeding.
Overdose
Symptoms: impaired consciousness, nausea, vomiting, epigastric pain, bleeding in the gastrointestinal tract, acute renal failure, hepatic failure, respiratory arrest, asystole.
Treatment: There are no specific antidotes and antagonists. Forced urine output, alkaline urination, hemodialysis is ineffective due to the high association of the drug with blood proteins.
Storage Conditions
In a dark place at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Shelf life
5 years.
Deystvuyushtee substance
Meloxicam
Terms and conditions
prescription
dosage form
injection
Prescribing
Prescribing
For adults as prescribed by a doctor
Solution for intramuscular administration.
Packing
3 amp. 2.5 ml each.
Pharmacological action
Meloxicam is an NSAID that has anti-inflammatory, antipyretic and analgesic effects. Belongs to the class of oxycams, is a derivative of enolic acid.
The mechanism of action is associated with the inhibition of prostaglandin synthesis as a result of selective inhibition of the enzymatic activity of type 2 cyclooxygenase (COX-2), which is involved in prostaglandin biosynthesis in the area of inflammation. When prescribed in high doses, prolonged use and individual characteristics of the body, selectivity for COX-2 is reduced. To a lesser extent, it affects the first type cyclooxygenase (COX-1), which is involved in the synthesis of prostaglandins that protect the gastrointestinal mucosa and take part in the regulation of blood flow in the kidneys. Due to the indicated selectivity of suppressing the activity of COX-2, the drug less often causes erosive and ulcerative lesions of the gastrointestinal tract.
Indications
Symptomatic treatment of inflammatory and degenerative diseases of the muscular-joint system associated with pain, including:
Osteoarthritis.
Rheumatoid Arthritis.
Ankylosing spondylitis (ankylosing spondylitis).
Osteochondrosis.
Contraindications
Hypersensitivity to meloxicam or auxiliary components of the drug.
Uncompensated heart failure.
Early postoperative period after coronary artery bypass grafting.
Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs.
Exacerbation of peptic ulcer of the stomach and duodenum active gastrointestinal bleeding.
Inflammatory bowel disease (ulcerative colitis, Crohn's disease in the acute stage).
Cerebrovascular bleeding or other bleeding.
Hemophilia and other bleeding disorders.
Severe liver failure or active liver disease.
Chronic renal failure (in patients not undergoing hemodialysis (creatinine clearance less than 30 ml / min)).
Progressive kidney disease, including confirmed hyperkalemia.
Children under 18 years old.
Pregnancy.
Breastfeeding period.
Precautions: in elderly patients and with the following medical history: coronary heart disease, congestive heart failure, cerebrovascular disease, peripheral artery disease, dyslipidemia / hyperlipidemia, diabetes mellitus, chronic renal failure (creatinine clearance 30-60 ml / min) ulcerative lesion of the gastrointestinal tract, the presence of Helicobacter pylori infection, smoking, severe somatic diseases. With prolonged use of NSAIDs, alcohol abuse, concomitant therapy with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., acetylsalicylic acid, clopidogrel), oral glucocorticosteroids (e.g., prednisolone), selective serotonin reuptake inhibitors (e.g., serotonoxinfram, ) the drug should be taken with caution. To reduce the risk of developing adverse effects from the gastrointestinal tract, the minimum effective dose should be used in a short course.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
The drug can change the properties of platelets, but does not replace the preventive effect of acetylsalicylic acid in cardiovascular diseases.
Caution should be exercised when using the drug in patients with a history of gastric and duodenal ulcer and patients on anticoagulant therapy. In such patients, the risk of erosive and ulcerative diseases of the gastrointestinal tract is increased.
Caution should be exercised and daily diuresis and renal function should be monitored when using the drug in the elderly and patients with reduced BCC and reduced glomerular filtration (dehydration, chronic heart failure, cirrhosis of the liver, nephrotic syndrome, clinically pronounced kidney disease, diuretics, dehydration after major surgical operations).
When signs of liver damage appear (skin itching, yellowing of the skin, nausea, vomiting, abdominal pain, dark urine, persistent and significant increase in the level of transaminases and changes in other indicators of liver function), the drug should be stopped and consult your doctor.
After two weeks of using the drug, it is necessary to control the activity of “liver” enzymes.
In patients with a slight or moderate decrease in renal function (CC> 30 ml / min), dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (pruritus, skin rash, urticaria, photosensitivity)
In patients with a slight or moderate decrease in renal function (CC> 30 ml / min), dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (pruritus, skin rash, urticaria, photosensitivity)
In patients with a slight or moderate decrease in renal function (CC> 30 ml / min), dose adjustment is not required.
Patients taking both diuretics and meloxicam should take enough fluids.
In case of allergic reactions (pruritus, skin rash, urticaria, photosensitivity)during treatment it is necessary to consult a doctor in order to resolve the issue of discontinuation of the drug.
Meloxicam, like other NSAIDs, can mask the symptoms of infectious diseases.
The use of meloxicam, as well as other drugs that block the synthesis of prostaglandins, can affect fertility, therefore it is not recommended for women planning pregnancy.
Do not use the drug concurrently with other NSAIDs.
Influence on the ability to drive vehicles and control mechanisms
The use of the drug can cause headaches, dizziness and drowsiness. If these phenomena occur, you should refuse to drive vehicles and perform other potentially dangerous activities, requiring increased concentration of attention and speed of psychomotor reactions.
Composition
1 ml of the solution contains:
Active ingredient: meloxicam - 6 mg.
Excipients: glycofurfural (glycofurol) 100 mg, glycine 5 mg, meglumine 3.75 mg, sodium hydroxide solution 1M to pH 8.2-8.9, sodium chloride 3 mg, poloxamer 188 (lutrol F68) 50 mg, water d / and up to 1 ml.
Dosage and administration of
Intramuscular administration of the drug is indicated in the first 2-3 days of treatment. Further treatment is continued with the use of oral forms (tablets). The recommended dose is 7.5 or 15 mg once a day, depending on the intensity of the pain and the severity of the inflammatory process. Since the potential risk of adverse reactions depends on the dose and duration of treatment, the smallest effective doses and the shortest possible short course should be used.
In patients with severe renal failure undergoing hemodialysis, the dose should not exceed 7.5 mg per day.
The drug is administered by deep IM injection. The contents of the ampoules should not be mixed in the same syringe with other drugs. The drug can not be entered in / in.
Side effects of
From the digestive system: more than 1% - dyspepsia, including nausea, vomiting, abdominal pain, diarrhea, constipation, flatulence 0.1-1% - a transient increase in the activity of “liver” transaminases, hyperbilirubinemia, belching, esophagitis, gastric or duodenal ulcer, gastrointestinal bleeding (hidden or overt ), stomatitis less than 0.1% - perforation of the digestive tract, colitis, hepatitis, gastritis.
From the hemopoietic organs: more than 1% - anemia 0.1-1% - leukopenia, thrombocytopenia.
From the skin: more than 1% - itching, skin rash 0.1-1% - urticaria less than 0.1% - photosensitivity, bullous rashes, erythema multiforme, incl. Stevens-Johnson syndrome, toxic epidermal necrolysis.
From the respiratory system: less than 0.1% - bronchospasm.
From the central nervous system: more than 1% - dizziness, headache 0.1-1% - tinnitus, drowsiness less than 0.1% - emotional lability, confusion, disorientation.
From the cardiovascular system: more than 1% - peripheral edema 0.1-1% - increased blood pressure, palpitations, hyperemia of the face.
From the urinary system: 0.1-1% - hypercreatininemia, increased serum urea concentration less than 0.1% - acute renal failure, no connection with meloxicam intake - interstitial nephritis, albuminuria, hematuria.
From the sensory organs: less than 0.1% - conjunctivitis, blurred vision.
Allergic reactions: less than 0.1% - angioedema, anaphylactic, anaphylactoid reactions.
Drug Interactions
When used simultaneously with other NSAIDs (including acetylsalicylic acid), the risk of erosive and ulcerative lesions and gastrointestinal bleeding increases.
With simultaneous use with antihypertensive drugs, the effectiveness of the latter may decrease.
With simultaneous use with lithium preparations, it is possible to develop cumulation of lithium and increase its toxic effect (it is recommended to control the concentration of lithium in the blood).
With simultaneous use with methotrexate, the side effect of the latter on the hematopoietic system is enhanced (the risk of anemia and leukopenia, a periodic general blood test is indicated).
When used simultaneously with diuretics and cyclosporine, the risk of developing renal failure increases.
With simultaneous use with intrauterine contraceptives, the effectiveness of the latter may be reduced.
When used simultaneously with anticoagulants (heparin, warfarin), thrombolytic drugs (streptokinase, fibrinolysin), and antiplatelet agents (ticlopidine, clopidogrel, acetysalicylic acid), the risk of bleeding increases (periodic monitoring of blood coagulability is necessary).
With simultaneous use with colestyramine, the excretion of meloxicam through the gastrointestinal tract is accelerated.
Concomitant use with selective serotonin reuptake inhibitors increases the risk of gastrointestinal bleeding.
Overdose
Symptoms: impaired consciousness, nausea, vomiting, epigastric pain, bleeding in the gastrointestinal tract, acute renal failure, hepatic failure, respiratory arrest, asystole.
Treatment: There are no specific antidotes and antagonists. Forced urine output, alkaline urination, hemodialysis is ineffective due to the high association of the drug with blood proteins.
Storage Conditions
In a dark place at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Shelf life
5 years.
Deystvuyushtee substance
Meloxicam
Terms and conditions
prescription
dosage form
injection
Prescribing
Prescribing
For adults as prescribed by a doctor
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review